DOCSLIB.ORG

Guide to the Application of Genotyping to Tuberculosis Prevention and Control

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guide to the Application of Genotyping to Tuberculosis Prevention and Control Guide to the Application of Genotyping to Tuberculosis Prevention and Control Handbook for TB Controllers, Epidemiologists, Laboratorians, and Other Program Staff Prepared by the National Tuberculosis Controllers Association / Centers for Disease Control and Prevention Advisory Group on Tuberculosis Genotyping June 2004 An electronic copy of this guide, the Isolate Submission Form, and other genotyping documents can be downloaded from the CDC Tuberculosis Genotyping Program’s WebBoard at http://web-tb.forum.cdc.gov Copies of the guide can be ordered by sending an e-mail to Dr. Patrick Moonan at [email protected]. Suggested citation: National TB Controllers Association / CDC Advisory Group on Tuberculosis Genotyping. Guide to the Application of Genotyping to Tuberculosis Prevention and Control. Atlanta, GA: US Department of Health and Human Services, CDC; June 2004. TM Contents Acknowledgments ...........................................................................................................iii 1. Introduction to Tuberculosis Genotyping ...............................................................1 Introduction to this Guide Overview of Tuberculosis Genotyping Overview of the CDC Tuberculosis Genotyping Program TB Program Eligibility and Application Procedures 2. Tuberculosis Genotyping Case Studies ..................................................................5 Investigation of a Genotyping Cluster in a Low-Incidence State Apparent Genotyping Cluster among Recent Immigrants from the Philippines False-Positive Culture Investigation Algorithm to Detect False-Positive Cultures A Misdiagnosis that was Identified with Genotyping Genotyping Used to Improve Contact and Cluster Investigations Identification of Nontraditional Transmission Settings Investigation of a Multistate Tuberculosis Outbreak Homeless Shelter Outbreak Investigation Using Genotyping to Evaluate the Impact of a Screening Program 3. CDC Tuberculosis Genotyping Laboratory Procedures ......................................15 Science behind Tuberculosis Genotyping Description of Genotyping Methods Submission of Isolates Genotyping Results, Designation of Clusters, and Reporting Suspected False-Positive Cultures IS6110-based RFLP Analysis 4. Combining Genotyping and Epidemiologic Data to Improve Our Understanding of Tuberculosis Transmission ................................................25 Definitions Reading the Genotyping Laboratory Report Comparing Genotyping and Epidemiologic Results from Two TB Patients Comparing Genotyping and Epidemiologic Results from Three or More TB Patients Clustering as a Surrogate Measure of Recent Transmission 5. Developing a Tuberculosis Genotyping Program .................................................35 Developing a Written Plan Initial Decisions Establishing Procedures for: • Submitting Isolates • Receiving and Acting on Genotyping Results • Requesting RFLP Analysis • Submitting Additional Isolates from the Same Patient Comparing Genotyping Results between Jurisdictions False-Positive Cultures Database Management and Quality Control Special Issues i 6. Applying Genotyping Results to Tuberculosis Control Practices ......................49 Evaluating Matching Genotypes Evaluating Nonmatching Genotypes Suspected False-Positive Culture Investigations Expanded Contact Investigations Outbreak Investigations Cluster Investigations Monitoring Trends 7. Appendices ...............................................................................................................63 Appendix A: Glossary and Abbreviations Appendix B: References and Useful Resources ii Acknowledgments The contents of this guide represent the dedication and hard work of our TB control community. Numerous people, despite having limited resources and working overtime on numerous competing projects, have contributed to the multiple tasks involved in bringing material of this complexity together into what we hope is a coherent whole. The editors gratefully acknowledge each contributor. We also acknowledge and thank Angie Weaver and Rachel Wilson for their excellent editorial contributions to the guide. Editors Thomas Navin, MD National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA Lisa Rosenblum, MD, MPH National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA Charles Wallace, PhD TB Elimination Division Texas Department of Health Austin, TX Sue Etkind, RN, MS TB Control and Prevention Massachusetts Department of Health and Human Service Jamaica Plain, MA iii Writing Group Members Jack Crawford, PhD Scott McNabb, PhD, MS National Center for HIV, STD, and TB Prevention National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Centers for Disease Control and Prevention Atlanta, GA Atlanta, GA Wendy Cronin, PhD Tanya Oemig, NRM Maryland State Department of Health and Mental Wisconsin Department of Health and Family Hygiene Services Baltimore, MD Madison, WI Jeff Driscoll, PhD Margaret Oxtoby, MD, MPH Wadsworth Center Bureau of TB Control New York State Department of Health New York State Department of Health Albany, NY Albany, NY Cynthia Driver, RN, MPH Walter Page Epidemiology Office National Tuberculosis Controllers Association Bureau of TB Control Atlanta, GA New York City Department of Health New York, NY Jennifer Flood, MD California Department of Health Services Berkeley, CA Reuben Granich, MD, MPH National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA Kashef Ijaz, MD, MPH National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA Steve Kammerer National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA Peter McElroy, PhD, MPH National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA iv Working Group Members Tracy Agerton, RN, MPH Barry Kreiswirth, PhD TB Control Program Public Health Research Institute New York City Department of Health Newark, NJ New York, NY Mark Lobato, MD Peter Barnes, MD National Center for HIV, STD, and TB Prevention Center for Pulmonary and Infectious Disease Control Centers for Disease Control and Prevention Departments of Medicine, Cell Biology, and Atlanta, GA Immunology University of Texas Health Center Bereneice M. Madison, PhD Tyler, TX National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Carol Berglund Atlanta, GA National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Beverly Metchock, DrPH Atlanta, GA National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Chris Braden, MD Atlanta, GA National Center for Infectious Diseases Centers for Disease Control and Prevention DeNay Porter-Kirkpatrick, MSN Atlanta, GA The University of Alabama at Birmingham Birmingham, AL Bill Burman, MD Denver Public Health and Hospitals Authority Sandy Price Denver, CO National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Don Cave, PhD Atlanta, GA University of Arkansas for Medical Sciences Little Rock, AR Sharon Sharnprapai, MS State Laboratory Institute Jeanne Courval, PhD Jamaica Plain, MA National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Sumi Sun, MPH Atlanta, GA California Department of Health Berkeley, CA Don Cunningham, BS Division of Tuberculosis Zachary Taylor, MD, MPH Arkansas Department of Health National Center for HIV, STD, and TB Prevention Little Rock, AR Centers for Disease Control and Prevention Atlanta, GA Ed Desmond, PhD California Department of Health Wanda Walton, MEd, PhD Berkeley, CA National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Loretta H. Gossett, RN, MA Atlanta, GA Anne Arundel County Department of Health Annapolis, MD Nancy G. Warren, PhD Bureau of Laboratories Nancy Hooper, BA Pennsylvania Department of Health Maryland Department of Health and Mental Hygiene Lionville, PA Baltimore, MD Rosemary Humes, MS, MT (ASCP), SM Liaison to Association of Public Health Laboratories Washington, DC v Technical Consultants Gabrielle Benenson, MPH National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA Melanie Davis, MS National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA Hsin-Hsin Foo, MPH National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA Michele Huitric, MPH National Center for HIV, STD, and TB Prevention Centers for Disease Control and Prevention Atlanta, GA vi Introduction to Tuberculosis Genotyping 1 Introduction to Tuberculosis Genotyping Chapter Preview 1. Introduction to this Guide 2. Overview of Tuberculosis Genotyping 3. Overview of the CDC Tuberculosis Genotyping Program 4. TB Program Eligibility and Application Procedures 1. Introduction to this Guide This guide provides an introduction to the application of tuberculosis (TB) genotyping to TB control practices and to the Centers for Disease Control and Prevention (CDC) TB Genotyping Program. It was written by the National Tuberculosis Controllers Association (NTCA)/CDC Advisory Group on Tuberculosis Genotyping and is intended for TB controllers, epidemiologists, laboratorians, and other program staff members who will be involved in submitting isolates for genotyping, analyzing and responding
Load more

Recommended publications
  • GENOME GENERATION Glossary
    GENOME GENERATION Glossary Chromosome An organism’s DNA is packaged into chromosomes. Humans have 23 pairs of chromosomesincluding one pair of sex chromosomes. Women have two X chromosomes and men have one X and one Y chromosome. Dominant (see also recessive) Genes come in pairs. A dominant form of a gene is the “stronger” version that will be expressed. Therefore if someone has one dominant and one recessive form of a gene, only the characteristics of the dominant form will appear. DNA DNA is the long molecule that contains the genetic instructions for nearly all living things. Two strands of DNA are twisted together into a double helix. The DNA code is made up of four chemical letters (A, C, G and T) which are commonly referred to as bases or nucleotides. Gene A gene is a section of DNA that is the code for a specific biological component, usually a protein. Each gene may have several alternative forms. Each of us has two copies of most of our genes, one copy inherited from each parent. Most of our traits are the result of the combined effects of a number of different genes. Very few traits are the result of just one gene. Genetic sequence The precise order of letters (bases) in a section of DNA. Genome A genome is the complete DNA instructions for an organism. The human genome contains 3 billion DNA letters and approximately 23,000 genes. Genomics Genomics is the study of genomes. This includes not only the DNA sequence itself, but also an understanding of the function and regulation of genes both individually and in combination.
    [Show full text]
  • Pharmacogenetic Testing: a Tool for Personalized Drug Therapy Optimization
    pharmaceutics Review Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization Kristina A. Malsagova 1,* , Tatyana V. Butkova 1 , Arthur T. Kopylov 1 , Alexander A. Izotov 1, Natalia V. Potoldykova 2, Dmitry V. Enikeev 2, Vagarshak Grigoryan 2, Alexander Tarasov 3, Alexander A. Stepanov 1 and Anna L. Kaysheva 1 1 Biobanking Group, Branch of Institute of Biomedical Chemistry “Scientific and Education Center”, 109028 Moscow, Russia; [email protected] (T.V.B.); [email protected] (A.T.K.); [email protected] (A.A.I.); [email protected] (A.A.S.); [email protected] (A.L.K.) 2 Institute of Urology and Reproductive Health, Sechenov University, 119992 Moscow, Russia; [email protected] (N.V.P.); [email protected] (D.V.E.); [email protected] (V.G.) 3 Institute of Linguistics and Intercultural Communication, Sechenov University, 119992 Moscow, Russia; [email protected] * Correspondence: [email protected]; Tel.: +7-499-764-9878 Received: 2 November 2020; Accepted: 17 December 2020; Published: 19 December 2020 Abstract: Pharmacogenomics is a study of how the genome background is associated with drug resistance and how therapy strategy can be modified for a certain person to achieve benefit. The pharmacogenomics (PGx) testing becomes of great opportunity for physicians to make the proper decision regarding each non-trivial patient that does not respond to therapy. Although pharmacogenomics has become of growing interest to the healthcare market during the past five to ten years the exact mechanisms linking the genetic polymorphisms and observable responses to drug therapy are not always clear. Therefore, the success of PGx testing depends on the physician’s ability to understand the obtained results in a standardized way for each particular patient.
    [Show full text]
  • HIV Genotyping and Phenotyping AHS – M2093
    Corporate Medical Policy HIV Genotyping and Phenotyping AHS – M2093 File Name: HIV_genotyping_and_phenotyping Origination: 1/2019 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Description Human immunodeficiency virus (HIV) is an RNA retrovirus that infects human immune cells (specifically CD4 cells) causing progressive deterioration of the immune system ultimately leading to acquired immune deficiency syndrome (AIDS) characterized by susceptibility to opportunistic infections and HIV-related cancers (CDC, 2014). Related Policies Plasma HIV-1 and HIV-2 RNA Quantification for HIV Infection Scientific Background Human immunodeficiency virus (HIV) targets the immune system, eventually hindering the body’s ability to fight infections and diseases. If not treated, an HIV infection may lead to acquired immunodeficiency syndrome (AIDS) which is a condition caused by the virus. There are two main types of HIV: HIV-1 and HIV-2; both are genetically different. HIV-1 is more common and widespread than HIV-2. HIV replicates rapidly; a replication cycle rate of approximately one to two days ensures that after a single year, the virus in an infected individual may be 200 to 300 generations removed from the initial infection-causing virus (Coffin & Swanstrom, 2013). This leads to great genetic diversity of each HIV infection in a single individual. As an RNA retrovirus, HIV requires the use of a reverse transcriptase for replication purposes. A reverse transcriptase is an enzyme which generates complimentary DNA from an RNA template. This enzyme is error-prone with the overall single-step point mutation rate reaching ∼3.4 × 10−5 mutations per base per replication cycle (Mansky & Temin, 1995), leading to approximately one genome in three containing a mutation after each round of replication (some of which confer drug resistance).
    [Show full text]
  • Review of the Current State of Genetic Testing - a Living Resource
    Review of the Current State of Genetic Testing - A Living Resource Prepared by Liza Gershony, DVM, PhD and Anita Oberbauer, PhD of the University of California, Davis Editorial input by Leigh Anne Clark, PhD of Clemson University July, 2020 Contents Introduction .................................................................................................................................................. 1 I. The Basics ......................................................................................................................................... 2 II. Modes of Inheritance ....................................................................................................................... 7 a. Mendelian Inheritance and Punnett Squares ................................................................................. 7 b. Non-Mendelian Inheritance ........................................................................................................... 10 III. Genetic Selection and Populations ................................................................................................ 13 IV. Dog Breeds as Populations ............................................................................................................. 15 V. Canine Genetic Tests ...................................................................................................................... 16 a. Direct and Indirect Tests ................................................................................................................ 17 b. Single
    [Show full text]
  • Evaluation of Openarray™ As a Genotyping Method for Forensic DNA Phenotyping and Human Identification
    G C A T T A C G G C A T genes Article Evaluation of OpenArray™ as a Genotyping Method for Forensic DNA Phenotyping and Human Identification Michele Ragazzo 1, Giulio Puleri 1, Valeria Errichiello 1, Laura Manzo 1, Laura Luzzi 1 , Saverio Potenza 2 , Claudia Strafella 1,3 , Cristina Peconi 3, Fabio Nicastro 4 , Valerio Caputo 1 and Emiliano Giardina 1,3,* 1 Department of Biomedicine and Prevention, Tor Vergata University of Rome, 00133 Rome, Italy; [email protected] (M.R.); [email protected] (G.P.); [email protected] (V.E.); [email protected] (L.M.); [email protected] (L.L.); [email protected] (C.S.); [email protected] (V.C.) 2 Department of Biomedicine and Prevention, Section of Legal Medicine, Social Security and Forensic Toxicology, University of Rome Tor Vergata, 00133 Rome, Italy; [email protected] 3 Genomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy; [email protected] 4 Austech, 00153 Rome, Italy; [email protected] * Correspondence: [email protected] Abstract: A custom plate of OpenArray™ technology was evaluated to test 60 single-nucleotide polymorphisms (SNPs) validated for the prediction of eye color, hair color, and skin pigmentation, and for personal identification. The SNPs were selected from already validated subsets (Hirisplex-s, Precision ID Identity SNP Panel, and ForenSeq DNA Signature Prep Kit). The concordance rate and call rate for every SNP were calculated by analyzing 314 sequenced DNA samples. The sensitivity of the assay was assessed by preparing a dilution series of 10.0, 5.0, 1.0, and 0.5 ng.
    [Show full text]
  • Genotyping-By-Sequencing to Unlock Genetic Diversity and Population Structure in White Yam (Dioscorea Rotundata Poir.)
    agronomy Article Genotyping-by-Sequencing to Unlock Genetic Diversity and Population Structure in White Yam (Dioscorea rotundata Poir.) Ranjana Bhattacharjee 1,* , Paterne Agre 1 , Guillaume Bauchet 2, David De Koeyer 3, Antonio Lopez-Montes 1,4, P. Lava Kumar 1 , Michael Abberton 1, Patrick Adebola 5, Asrat Asfaw 5 and Robert Asiedu 1 1 International Institute of Tropical Agriculture, PMB 5320, Ibadan 200001, Nigeria; [email protected] (P.A.); [email protected] (A.L.-M.); [email protected] (P.L.K.); [email protected] (M.A.); [email protected] (R.A.) 2 Boyce Thompson Institute, Cornell University, Ithaca, NY 14853, USA; [email protected] 3 Agriculture and Agri-Food Canada, Fredericton, NB E3B 4Z7, Canada; [email protected] 4 International Trade Center, 29 Independence Avenue, Accra 00233, Ghana 5 International Institute of Tropical Agriculture, PMB 82, Kubuwa, Abuja 901101, Nigeria; [email protected] (P.A.); [email protected] (A.A.) * Correspondence: [email protected] Received: 7 August 2020; Accepted: 14 September 2020; Published: 22 September 2020 Abstract: White yam (Dioscorea rotundata Poir.) is one of the most important tuber crops in West Africa, where it is indigenous and represents the largest repository of biodiversity through several years of domestication, production, consumption, and trade. In this study, the genotyping-by-sequencing (GBS) approach was used to sequence 814 genotypes consisting of genebank landraces, breeding lines, and market varieties to understand the level of genetic diversity and pattern of the population structure among them. The genetic diversity among different genotypes was assessed using three complementary clustering methods, the model-based admixture, discriminant analysis of principal components (DAPC), and phylogenetic tree.
    [Show full text]
  • DNA Phenotyping and Kinship Determination
    DNA Phenotyping and Kinship Determination Ellen McRae Greytak, PhD Director of Bioinformatics Parabon NanoLabs, Inc. ©©2 2015015 ParabonParabon NanoLabs,NanoLabs Inc.Inc All rightsrights reserved. reserved Forensic Applications of DNA Phenotyping Predict a person’s ancestry and/or appearance (“phenotype”) from his or her DNA Generate investigative leads when DNA doesn’t match a database (e.g., CODIS) Gain additional information (e.g., pigmentation, detailed ancestry) about unidentified remains Main value is in excluding non-matching individuals to help narrow a suspect list Without information on age, weight, lifestyle, etc., phenotyping currently is not targeted toward individual identification Snapshot Workflow Workflow of a Parabon® Snapshot™ Investigation Unidentified Remains DNA Evidence Is Collected and Sent to Crime Lab DNA Evidence DNA Crime Lab CCrime Lab Extracts DNA And Produces STR Profile Checked STR Profile (a.k.a. “DNA Fingerprint”) AAgainst DNA Database(s) Yes Match No Found? SnapshotS Composite Ordered Extracted DNA ™ D N A PH E N O T Y P I N G DNA Service Labs Unidentified DNA Is Genotype Data Is Genotyping Lab Produces SNP Sent To Service Lab Sent To Parabon Profile (a.k.a. “DNA Blueprint”) (DNA Extracted If Needed) 50pg – 2ng DNA Evidence — or — Extracted DNA NOTE: STR Profiles Do Not Contain Sufficient Genetic Information to Produce A SNP Genotype Parabon NanoLabs PParabonb AnalyzesAl PParabon Predicts Physical Traits Investigator Uses Genotype Data and Produces Snapshot Report
    [Show full text]
  • Genotyping of Single Nucleotide Polymorphisms Using Allele
    diagnostics Article Genotyping of Single Nucleotide Polymorphisms Using Allele-Specific qPCR Producing Amplicons of Small Sizes Directly from Crude Serum Isolated from Capillary Blood by a Hand-Powered Paper Centrifuge Gustavo Barcelos Barra 1,2,*,† , Ticiane Henriques Santa Rita 1,2,†, Daniella Paniago Jardim 1,2,†, Pedro Góes Mesquita 1, Camila Santos Nobre 1,2, Rafael Henriques Jácomo 1 and Lídia Freire Abdalla Nery 1 1 Sabin Laboratory, Brasília 70632-300, Brazil; [email protected] (T.H.S.R.); [email protected] (D.P.J.); [email protected] (P.G.M.); [email protected] (C.S.N.); [email protected] (R.H.J.); [email protected] (L.F.A.N.) 2 Post-Graduation of Health Science, University of Brasília, Brasilia 70910-900, Brazil * Correspondence: [email protected] † These authors contributed equally to the study. Received: 15 November 2018; Accepted: 29 December 2018; Published: 11 January 2019 Abstract: The cell-free genomic DNA (gDNA) concentration in serum ranges from 1500 to 7500 copies/mL within 2 h after phlebotomy (6–24 times the concentration observed in plasma). Here, we aimed to evaluate the gDNA size distribution in serum with time after coagulation and to test if crude serum can be directly used as a source of gDNA for qPCR. Next, we investigated if single nucleotide polymorphisms (SNPs) could be genotyped directly from the crude serum isolated from capillary blood using a hand-powered paper centrifuge. All tested PCR targets (65, 100, 202 and 688 base pairs) could be successfully amplified from DNA extracted from serum, irrespective of their amplicon size.
    [Show full text]
  • Molecular Methods for Bacterial Genotyping and Analyzed Gene Regions
    42Journal of Microbiology and Infectious DiseasesYıldırım / İH et al. Molecular methods 2011; 1 (1): 42-46 JMID doi: 10.5799/ahinjs.02.2011.01.0011 REVIEW ARTICLE Molecular methods for bacterial genotyping and analyzed gene regions İbrahim Halil Yıldırım1, Seval Cing Yıldırım2, Nadir Koçak3 1Dicle University, Faculty of Veterinary Department of Genetics, Diyarbakır, Turkey 2İnönü University, Faculty of Science, Department of Biology, Malatya, Turkey 3Selçuk University, Selçuklu Medical Faculty, Department of Medical Genetics, Konya, Turkey ABSTRACT Bacterial strain typing is an important process for diagnosis, treatment and epidemiological investigations. Current bacterial strain typing methods may be classified into two main categories: phenotyping and genotyping. Phenotypic characters are the reflection of genetic contents. Genotyping, which refers discrimination of bacterial strains based on their genetic content, has recently become widely used for bacterial strain typing. The methods already used in geno- typing of bacteria are quite different from each other. In this review we tried to summarize the basic principles of DNA- based methods used in genotyping of bacteria and describe some important DNA regions that are used in genotyping of bacteria. J Microbiol Infect Dis 2011;1(1):42-46. Key words: Bacterial genotyping, pulsed-field gel electrophoresis, internal transcribed region (ITS) Bakteri genotiplendirmesinde kullanılan moleküler yöntemler ve incelenen gen bölgeleri ÖZET Bakteri tiplendirilmesi tanı, tedavi ve epidemiyolojik araştırmalar için önemli bir süreçtir. Mevcut bakteriyal suş tiplendir- me yöntemleri iki ana kategoride sınıflandırılabilir: fenotipleme ve genotipleme. Fenotipik karakterler genetik içeriğin yansımasıdır. Bakterilerin genetik içeriklerine bağlı olarak sınıflandırılması olan genotiplendirme son dönemlerde bak- teri tiplendirmesinde sıklıkla kullanılmaktadır. Bakteri genotiplendirmesinde kullanılan yöntemler birbirlerinden oldukça farklıdır.
    [Show full text]
  • Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling
    Guidance for Industry Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) January 2013 Clinical Pharmacology Clinical/Medical 10300.fnl.doc Guidance for Industry Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 10903 New Hampshire Ave. Silver Spring, MD 20993-0002 Phone: 301-796-3400; Fax 301-847-8714 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or Office of Communication, Outreach, and Development (HFM-40) Center for Biologics Evaluation and Research Food and Drug Administration 1401 Rockville Pike, Rockville, MD 20852-1448 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (Tel) 800-835-4709 or 301-827-1800 or Office of Communication, Education, and Radiation Programs Division of Small Manufacturers, International and Consumer Assistance Center for Devices and Radiological Health Food and Drug Administration 10903 New Hampshire Ave. WO66, Room 4613 Silver Spring, MD 20993-0002 http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm Email: [email protected] Fax: 301-827-8149 (Tel) Manufacturers Assistance: 800-638-2041 or 301-796-7100 (Tel) International Staff: 301-796-5708 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Center for Devices and Radiological Health (CDRH) January 2013 Clinical Pharmacology Clinical/Medical TABLE OF CONTENTS I.
    [Show full text]
  • Genotyping Bacterial and Fungal Pathogens Using Sequence Variation in the Gene for the CCA-Adding Enzyme Paul Franz, Heike Betat and Mario Mörl*
    Franz et al. BMC Microbiology (2016) 16:47 DOI 10.1186/s12866-016-0670-2 METHODOLOGY ARTICLE Open Access Genotyping bacterial and fungal pathogens using sequence variation in the gene for the CCA-adding enzyme Paul Franz, Heike Betat and Mario Mörl* Abstract Background: To allow an immediate treatment of an infection with suitable antibiotics and bactericides or fungicides, there is an urgent need for fast and precise identification of the causative human pathogens. Methods based on DNA sequence comparison like 16S rRNA analysis have become standard tools for pathogen verification. However, the distinction of closely related organisms remains a challenging task. To overcome such limitations, we identified a new genomic target sequence located in the single copy gene for tRNA nucleotidyltransferase fulfilling the requirements for a ubiquitous, yet highly specific DNA marker. In the present study, we demonstrate that this sequence marker has a higher discriminating potential than commonly used genotyping markers in pro- as well as eukaryotes, underscoring its applicability as an excellent diagnostic tool in infectology. Results: Based on phylogenetic analyses, a region within the gene for tRNA nucleotidyltransferase (CCA-adding enzyme) was identified as highly heterogeneous. As prominent examples for pro- and eukaryotic pathogens, several Vibrio and Aspergillus species were used for genotyping and identification in a multiplex PCR approach followed by gel electrophoresis and fluorescence-based product detection. Compared to rRNA analysis, the selected gene region of the tRNA nucleotidyltransferase revealed a seven to 30-fold higher distinction potential between closely related Vibrio or Aspergillus species, respectively. The obtained data exhibit a superb genome specificity in the diagnostic analysis.
    [Show full text]
  • Single Nucleotide Polymorphism Genotyping: Biochemistry, Protocol, Cost and Throughput
    The Pharmacogenomics Journal (2003) 3, 77–96 & 2003 Nature Publishing Group All rights reserved 1470-269X/03 $25.00 www.nature.com/tpj REVIEW Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput X Chen ABSTRACT The large number of single nucleotide polymorphism (SNP) markers available PF Sullivan in the public databases makes studies of association and fine mapping of Department of Psychiatry, Virginia Institute for disease loci very practical. To provide information for researchers who do not Psychiatric and Behavioral Genetics, Virginia follow SNP genotyping technologies but need to use them for their research, Commonwealth University, Richmond, VA, USA we review here recent developments in the fields. We start with a general description of SNP typing protocols and follow this with a summary of Correspondence: current methods for each step of the protocol and point out the unique Dr X Chen, Department of Psychiatry, Virginia Institute for Psychiatric and features and weaknesses of these techniques as well as comparing the cost Behavioral Genetics, Virginia and throughput structures of the technologies. Finally, we describe some Commonwealth University, 800 E. Leigh popular techniques and the applications that are suitable for these Street, Richmond, VA 23298-0424, USA Tel: techniques. +1 804 828 8124 Fax: +1 804 828 3223 E-mail: [email protected] The Pharmacogenomics Journal (2003) 3, 77–96. doi:10.1038/sj.tpj.6500167 Keywords: SNP; genotyping; allele discrimination; cost; throughput INTRODUCTION Single nucleotide polymorphisms (SNPs) have emerged as genetic markers of choice because of their high-density and relatively even distribution in the human genomes1–3 and have been used by many groups for fine mapping disease loci and for candidate gene association studies.
    [Show full text]